Global Interventional Oncology Market

Interventional Oncology Comprehensive Study by Cancer Type (Lung Cancer, Liver Cancer, Kidney Cancer, Other), Procedure Type (Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ), Radiation Therapy, Particle Embolization) Players and Region - Global Market Outlook to 2030

Interventional Oncology Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Interventional Oncology
Interventional oncology, most rapidly growing procedures for diagnosis and treatment of cancer with the help of interventional radiology and minimally invasive procedures that are conducted under image guidance. The process utilizes various equipment including x-ray, ultrasound, computed tomography, or magnetic resonance imaging for guidance purposes. The procedures are carried out using numerous guide accessories and instruments such as ablation electrodes, guidewires, biopsy needles, and intravascular catheters that enable the treatment of a tumor situated in remote parts of the body.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Billion)
CAGR6.7%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Interventional Oncology market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

BTG plc (United Kingdom), Medtronic (Ireland), Boston Scientific (United States), Terumo (Japan), Merit Medical (United States), Sirtex (China), AngioDynamics (United States), Ethicon (United States), Teleflex (United States), Cook Medical (United States), HealthTronics (United States), MedWaves Medical (United States), Sanarus (United States), IMBiotechnologies (Canada), Trod Medical (United States), IceCure Medical (Israel) and Mermaid Medicals (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (United States), Endo Shape (United States), Monteris Medical (United States), Interface Biomaterials BV (Netherlands), Instylla (United States) and Trisalus Lifesciences (United States).

Segmentation Overview
AMA Research has segmented the market of Global Interventional Oncology market by and Region.



On the basis of geography, the market of Interventional Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Cancer Type, the sub-segment i.e. Lung Cancer will boost the Interventional Oncology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Procedure Type, the sub-segment i.e. Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ) will boost the Interventional Oncology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Interventional Oncology and Personalized Or Precision Interventional Oncology

Market Growth Drivers:
Rising Patient Preference for Minimally Invasive Procedures, Expansion of the Target Patient Population and Increasing Public-Private Funding and Government Support for Interventional Oncology

Challenges:
Limited Clinical Data to Support Therapeutic Efficacy and Strong Market Positioning of Alternative Therapies

Restraints:
Dearth of Well-Trained and Skilled Radiologists and Oncologists and Unfavorable Regulations

Opportunities:
Emerging Economies Offer High Growth Potential and Rising Awareness About the Benefits of Interventional Oncology

Market Leaders and their expansionary development strategies
In July 2020, Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors.The acquisition of Quirem Medical further strengthens our business, expands on our manufacturing and clinical development activities, and complements our comprehensive suite of offerings to support our customers.
In April 2021, Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team. This reflects Terumo's aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient's quality of life and survival.


Key Target Audience
Cancer Drug Manufacturers, Drug Distributor/Suppliers, Research Organizations, Government Regulatory Body and Other

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Cancer Type
  • Lung Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other

By Procedure Type
  • Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation )
  • Radiation Therapy
  • Particle Embolization

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Patient Preference for Minimally Invasive Procedures
      • 3.2.2. Expansion of the Target Patient Population
      • 3.2.3. Increasing Public-Private Funding and Government Support for Interventional Oncology
    • 3.3. Market Challenges
      • 3.3.1. Limited Clinical Data to Support Therapeutic Efficacy
      • 3.3.2. Strong Market Positioning of Alternative Therapies
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Interventional Oncology
      • 3.4.2. Personalized Or Precision Interventional Oncology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Interventional Oncology, by Cancer Type, Procedure Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Interventional Oncology (Value)
      • 5.2.1. Global Interventional Oncology by: Cancer Type (Value)
        • 5.2.1.1. Lung Cancer
        • 5.2.1.2. Liver Cancer
        • 5.2.1.3. Kidney Cancer
        • 5.2.1.4. Other
      • 5.2.2. Global Interventional Oncology by: Procedure Type (Value)
        • 5.2.2.1. Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation )
        • 5.2.2.2. Radiation Therapy
        • 5.2.2.3. Particle Embolization
      • 5.2.3. Global Interventional Oncology Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Interventional Oncology (Price)
  • 6. Interventional Oncology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BTG plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Terumo (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merit Medical (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sirtex (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AngioDynamics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ethicon (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teleflex (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cook Medical (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. HealthTronics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. MedWaves Medical (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Sanarus (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. IMBiotechnologies (Canada)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Trod Medical (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. IceCure Medical (Israel)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Mermaid Medicals (Denmark)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Interventional Oncology Sale, by Cancer Type, Procedure Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Interventional Oncology (Value)
      • 7.2.1. Global Interventional Oncology by: Cancer Type (Value)
        • 7.2.1.1. Lung Cancer
        • 7.2.1.2. Liver Cancer
        • 7.2.1.3. Kidney Cancer
        • 7.2.1.4. Other
      • 7.2.2. Global Interventional Oncology by: Procedure Type (Value)
        • 7.2.2.1. Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation )
        • 7.2.2.2. Radiation Therapy
        • 7.2.2.3. Particle Embolization
      • 7.2.3. Global Interventional Oncology Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Interventional Oncology (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Interventional Oncology: by Cancer Type(USD Billion)
  • Table 2. Interventional Oncology Lung Cancer , by Region USD Billion (2018-2023)
  • Table 3. Interventional Oncology Liver Cancer , by Region USD Billion (2018-2023)
  • Table 4. Interventional Oncology Kidney Cancer , by Region USD Billion (2018-2023)
  • Table 5. Interventional Oncology Other , by Region USD Billion (2018-2023)
  • Table 6. Interventional Oncology: by Procedure Type(USD Billion)
  • Table 7. Interventional Oncology Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ) , by Region USD Billion (2018-2023)
  • Table 8. Interventional Oncology Radiation Therapy , by Region USD Billion (2018-2023)
  • Table 9. Interventional Oncology Particle Embolization , by Region USD Billion (2018-2023)
  • Table 10. South America Interventional Oncology, by Country USD Billion (2018-2023)
  • Table 11. South America Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 12. South America Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 13. Brazil Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 14. Brazil Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 15. Argentina Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 16. Argentina Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 17. Rest of South America Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 18. Rest of South America Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 19. Asia Pacific Interventional Oncology, by Country USD Billion (2018-2023)
  • Table 20. Asia Pacific Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 21. Asia Pacific Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 22. China Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 23. China Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 24. Japan Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 25. Japan Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 26. India Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 27. India Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 28. South Korea Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 29. South Korea Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 30. Taiwan Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 31. Taiwan Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 32. Australia Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 33. Australia Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 34. Rest of Asia-Pacific Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 35. Rest of Asia-Pacific Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 36. Europe Interventional Oncology, by Country USD Billion (2018-2023)
  • Table 37. Europe Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 38. Europe Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 39. Germany Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 40. Germany Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 41. France Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 42. France Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 43. Italy Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 44. Italy Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 45. United Kingdom Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 46. United Kingdom Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 47. Netherlands Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 48. Netherlands Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 49. Rest of Europe Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 50. Rest of Europe Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 51. MEA Interventional Oncology, by Country USD Billion (2018-2023)
  • Table 52. MEA Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 53. MEA Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 54. Middle East Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 55. Middle East Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 56. Africa Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 57. Africa Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 58. North America Interventional Oncology, by Country USD Billion (2018-2023)
  • Table 59. North America Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 60. North America Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 61. United States Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 62. United States Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 63. Canada Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 64. Canada Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 65. Mexico Interventional Oncology, by Cancer Type USD Billion (2018-2023)
  • Table 66. Mexico Interventional Oncology, by Procedure Type USD Billion (2018-2023)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Interventional Oncology: by Cancer Type(USD Billion)
  • Table 85. Interventional Oncology Lung Cancer , by Region USD Billion (2025-2030)
  • Table 86. Interventional Oncology Liver Cancer , by Region USD Billion (2025-2030)
  • Table 87. Interventional Oncology Kidney Cancer , by Region USD Billion (2025-2030)
  • Table 88. Interventional Oncology Other , by Region USD Billion (2025-2030)
  • Table 89. Interventional Oncology: by Procedure Type(USD Billion)
  • Table 90. Interventional Oncology Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ) , by Region USD Billion (2025-2030)
  • Table 91. Interventional Oncology Radiation Therapy , by Region USD Billion (2025-2030)
  • Table 92. Interventional Oncology Particle Embolization , by Region USD Billion (2025-2030)
  • Table 93. South America Interventional Oncology, by Country USD Billion (2025-2030)
  • Table 94. South America Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 95. South America Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 96. Brazil Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 97. Brazil Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 98. Argentina Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 99. Argentina Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 100. Rest of South America Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 101. Rest of South America Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 102. Asia Pacific Interventional Oncology, by Country USD Billion (2025-2030)
  • Table 103. Asia Pacific Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 104. Asia Pacific Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 105. China Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 106. China Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 107. Japan Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 108. Japan Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 109. India Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 110. India Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 111. South Korea Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 112. South Korea Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 113. Taiwan Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 114. Taiwan Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 115. Australia Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 116. Australia Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 117. Rest of Asia-Pacific Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 118. Rest of Asia-Pacific Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 119. Europe Interventional Oncology, by Country USD Billion (2025-2030)
  • Table 120. Europe Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 121. Europe Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 122. Germany Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 123. Germany Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 124. France Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 125. France Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 126. Italy Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 127. Italy Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 128. United Kingdom Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 129. United Kingdom Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 130. Netherlands Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 131. Netherlands Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 132. Rest of Europe Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 133. Rest of Europe Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 134. MEA Interventional Oncology, by Country USD Billion (2025-2030)
  • Table 135. MEA Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 136. MEA Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 137. Middle East Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 138. Middle East Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 139. Africa Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 140. Africa Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 141. North America Interventional Oncology, by Country USD Billion (2025-2030)
  • Table 142. North America Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 143. North America Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 144. United States Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 145. United States Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 146. Canada Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 147. Canada Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 148. Mexico Interventional Oncology, by Cancer Type USD Billion (2025-2030)
  • Table 149. Mexico Interventional Oncology, by Procedure Type USD Billion (2025-2030)
  • Table 150. Research Programs/Design for This Report
  • Table 151. Key Data Information from Secondary Sources
  • Table 152. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Interventional Oncology: by Cancer Type USD Billion (2018-2023)
  • Figure 5. Global Interventional Oncology: by Procedure Type USD Billion (2018-2023)
  • Figure 6. South America Interventional Oncology Share (%), by Country
  • Figure 7. Asia Pacific Interventional Oncology Share (%), by Country
  • Figure 8. Europe Interventional Oncology Share (%), by Country
  • Figure 9. MEA Interventional Oncology Share (%), by Country
  • Figure 10. North America Interventional Oncology Share (%), by Country
  • Figure 11. Global Interventional Oncology share by Players 2023 (%)
  • Figure 12. Global Interventional Oncology share by Players (Top 3) 2023(%)
  • Figure 13. Global Interventional Oncology share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. BTG plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. BTG plc (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 18. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 19. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 20. Boston Scientific (United States) Revenue: by Geography 2023
  • Figure 21. Terumo (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Terumo (Japan) Revenue: by Geography 2023
  • Figure 23. Merit Medical (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merit Medical (United States) Revenue: by Geography 2023
  • Figure 25. Sirtex (China) Revenue, Net Income and Gross profit
  • Figure 26. Sirtex (China) Revenue: by Geography 2023
  • Figure 27. AngioDynamics (United States) Revenue, Net Income and Gross profit
  • Figure 28. AngioDynamics (United States) Revenue: by Geography 2023
  • Figure 29. Ethicon (United States) Revenue, Net Income and Gross profit
  • Figure 30. Ethicon (United States) Revenue: by Geography 2023
  • Figure 31. Teleflex (United States) Revenue, Net Income and Gross profit
  • Figure 32. Teleflex (United States) Revenue: by Geography 2023
  • Figure 33. Cook Medical (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cook Medical (United States) Revenue: by Geography 2023
  • Figure 35. HealthTronics (United States) Revenue, Net Income and Gross profit
  • Figure 36. HealthTronics (United States) Revenue: by Geography 2023
  • Figure 37. MedWaves Medical (United States) Revenue, Net Income and Gross profit
  • Figure 38. MedWaves Medical (United States) Revenue: by Geography 2023
  • Figure 39. Sanarus (United States) Revenue, Net Income and Gross profit
  • Figure 40. Sanarus (United States) Revenue: by Geography 2023
  • Figure 41. IMBiotechnologies (Canada) Revenue, Net Income and Gross profit
  • Figure 42. IMBiotechnologies (Canada) Revenue: by Geography 2023
  • Figure 43. Trod Medical (United States) Revenue, Net Income and Gross profit
  • Figure 44. Trod Medical (United States) Revenue: by Geography 2023
  • Figure 45. IceCure Medical (Israel) Revenue, Net Income and Gross profit
  • Figure 46. IceCure Medical (Israel) Revenue: by Geography 2023
  • Figure 47. Mermaid Medicals (Denmark) Revenue, Net Income and Gross profit
  • Figure 48. Mermaid Medicals (Denmark) Revenue: by Geography 2023
  • Figure 49. Global Interventional Oncology: by Cancer Type USD Billion (2025-2030)
  • Figure 50. Global Interventional Oncology: by Procedure Type USD Billion (2025-2030)
  • Figure 51. South America Interventional Oncology Share (%), by Country
  • Figure 52. Asia Pacific Interventional Oncology Share (%), by Country
  • Figure 53. Europe Interventional Oncology Share (%), by Country
  • Figure 54. MEA Interventional Oncology Share (%), by Country
  • Figure 55. North America Interventional Oncology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • BTG plc (United Kingdom)
  • Medtronic (Ireland)
  • Boston Scientific (United States)
  • Terumo (Japan)
  • Merit Medical (United States)
  • Sirtex (China)
  • AngioDynamics (United States)
  • Ethicon (United States)
  • Teleflex (United States)
  • Cook Medical (United States)
  • HealthTronics (United States)
  • MedWaves Medical (United States)
  • Sanarus (United States)
  • IMBiotechnologies (Canada)
  • Trod Medical (United States)
  • IceCure Medical (Israel)
  • Mermaid Medicals (Denmark)
Additional players considered in the study are as follows:
Guerbet (France) , ABK Biomedical (Canada) , Shape Memory Medical (United States) , Endo Shape (United States) , Monteris Medical (United States) , Interface Biomaterials BV (Netherlands) , Instylla (United States) , Trisalus Lifesciences (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 211 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Interventional Oncology Market Quantitative research analysis
Global Interventional Oncology Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as BTG plc (United Kingdom), Medtronic (Ireland), Boston Scientific (United States), Terumo (Japan), Merit Medical (United States), Sirtex (China), AngioDynamics (United States), Ethicon (United States), Teleflex (United States), Cook Medical (United States), HealthTronics (United States), MedWaves Medical (United States), Sanarus (United States), IMBiotechnologies (Canada), Trod Medical (United States), IceCure Medical (Israel) and Mermaid Medicals (Denmark) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Interventional Oncology " is seen as one of major influencing trends for Interventional Oncology Market during projected period 2023-2030.
The Interventional Oncology market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Interventional Oncology Market to reach USD3.1 Billion by 2030.

Know More About Global Interventional Oncology Market Report?

Have a Query? Click Here

Other Related Reports

Anti Diarrheal Drugs Comprehensive Study by Type (Prescription Drugs, OTC Drugs), Application (Children, Adults), Distribution Channel (Hospital, Pharmaceutical Clinics, Online Store) Players and Reg...
$ 3500
Ayurvedic Health and Personal Care Products Comprehensive Study by Type (Skin Care, Hair Care, Oral Care, Digestive Care, Others), Distribution Channels (Supermarkets and Hypermarkets, Drug Stores, S...
$ 3800
Endocrine Testing System Comprehensive Study by Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (HCG) Hormone Test, Luteinizing Hormone (LH) Test, Deh...
$ 3750
Mumps Vaccine Comprehensive Study by Type (Mono Vaccines, Combination Vaccines, Others), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Others), End User (Hospital, Pedi...
$ 3800
Vulvodynia Treatment Comprehensive Study by Application (Hospitals, Clinics, Others), Drugs (Local Anesthetics, Topical Estrogen, Tricyclic Antidepressants, Anticonvulsants, Nerve Blocks, Serotonin-N...
$ 3650
Atomic Emission Spectroscopy Comprehensive Study by Type (Flame Emission Spectroscopy, Plasma Emission Spectroscopy), Application (Foods And Drinks, Pharmaceutical Samples, Environmental Samples, Her...
$ 3800